Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia

Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia

Background: While the outcomes of chronic phase chronic myeloid leukemia (CP-CML) patients aged over 65 years have been extensively evaluated in real-life experiences, limited data exist for the very elderly population (i.e., aged ≥ 75 years), especially for next-generation tyrosine kinase inhibitor...

Full description

Bibliographic Details
Main Authors: Alessandro Costa, Elisabetta Abruzzese, Roberto Latagliata, Olga Mulas, Ida Carmosino, Emilia Scalzulli, Maria Laura Bisegna, Claudia Ielo, Maurizio Martelli, Giovanni Caocci, Massimo Breccia
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Journal of Clinical Medicine
Subjects:
chronic myeloid leukemia
tyrosine kinase inhibitor
very elderly
safety
efficacy
outcome
Online Access:https://www.mdpi.com/2077-0383/13/1/273

Internet

https://www.mdpi.com/2077-0383/13/1/273

Similar Items